Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: Bidirectional translational science

Journal of Cellular Physiology

Volumn 209, Issue 3, 2006, Pages 659-662

  Dezube, Bruce J ^a,b   Sullivan, Ryan ^a   Koon, Henry B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANGIOPOIETIN; BEVACIZUMAB; BORTEZOMIB; CHEMOKINE; G PROTEIN COUPLED RECEPTOR; IMATINIB; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEXAVAR; PLATELET DERIVED GROWTH FACTOR; PROTEIN SYNTHESIS INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SOMATOMEDIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; VEGLIN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; CANCER THERAPY; CELL GROWTH; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG TARGETING; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; KAPOSI SARCOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SEQUENCE HOMOLOGY; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR REGRESSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CLINICAL TRIALS; ENZYME INHIBITORS; HERPESVIRUS 8, HUMAN; HIV-1; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BIOSYNTHESIS; RECEPTORS, CHEMOKINE; SARCOMA, KAPOSI; VIRAL PROTEINS;

HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33750511729     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20795     Document Type: Short Survey

References (42)

1. Acker T, Plate KH. 2002. A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. J Mol Med 80:562-575.
2. Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, Silverstein RL, Rafii S, Mesri EA. 2003. Kaposfs sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 3(2):131-143.
3. Benelli R, Adatia R, Ensoli B, Stetler-Stevenson WG, Santi L, Albini A. 1994. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol Res 6:251-257.
4. Betsholtz C. 2004. Insight into the physiological functions of PDGP through genetic studies in mice. Cytokine Growth Factor Rev 15:215-228.
5. Blankaert D, Simonart T, Van Vooren JP, Parent D, Liesnard C, Farber CM, Marique T, Werenne J. 1998. Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 18:203-209.
6. Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, Yancopoulos GD. 2000. Expression of Tiel, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 156:2179-2183.
7. Burger M, Hartmann T, Burger JA, Schraufstatter I. 2005. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 24:2067-2075.
8. Catrina SB, Lewitt M, Massambu C, Dricu A, Grunler J, Axelson M, Biberfeld P, Brismar K. 2005. Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. Br J Cancer 92:1467-1474.
9. Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, Chang Y, Knowles DM. 1996, Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol 70:8218-8223.
10. Dadke D, Fryer BH, Golemis EA, Field J. 2003. Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res 63:8837-8847.
11. Deng H, Song MJ, Chu JT, Sun R. 2002. Transcriptional regulation of the interleukin-6 gene of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J Virol 76:8252-8264.
12. Dezube BJ, Pantanowitz L, Aboulafia DA. 2004, Management of AIDS-related Kaposi Sarcoma-advances in target discovery and treatment. AIDS Reader 14:236-253.
13. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM, 2006. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS Malignancy Consortium Study. J Clin Oncol 24:1389-1394.
14. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. 2006. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35.
15. Guertin DA, Sabatini DM. 2005, An expanding role for mTOR in cancer. Trends Mol Med 11:353-361.
16. Guo HG, Browning P, Nicholas J, Hayward GS, Tschachler E, Jiang YW, Sadowska M, Raffeld M, Colombini S, Gallo RC, Reitz MS Jr. 1997. Characterization of a chemokine receptor-related gene in human herpesvirus 8 and its expression in Kaposi's sarcoma. Virology 228:371-378.
17. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar EM, Kaufmann SH, Gottardis. M, Erlichman C. 2006. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66:362-371.
18. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. 2003. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710.
19. Hideshima T, Chauhan D, Teoh G, Raje N, Treon SP, Tai YT, Shima Y, Anderson KC. 2000. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res 6:1180-1189.
20. Ishihara K, Hirano T. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13:357-368.
21. Kim EJ, Shin HK, Park JH. 2005. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: A possible mechanism of the growth inhibitory effect of Genistein. J Med Food 8:431-438.
22. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ. 2005. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 23:982-989.
23. Larsson O, Girnita A, Girnita L. 2005. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92:2097-2101.
24. Luo JL, Kamata H, Karin M. 2005. IKK/NF-kappaB signaling: Balancing life and death - A new approach to cancer therapy. J Clin Invest 115:2625-2632.
25. Martin JN, Osmand DH. 1999. Kaposi's sarcoma associated herpesvirus and sexual transmission of cancer risk. Curr Opin Oncol 11:508-515.
26. Masood R, Cesarman E, Smith DL, Gill PS, Flore O. 2002. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol 160; 23-29.
27. Meads MB, Medveczky PG. 2004. Kaposi's sarcoma-associated herpesvirus-encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: Evidence for a unique autocrine signaling mechanism. J Biol Chem 279:51793-51803.
28. Mesri EA. 1999. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: A missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood 93; 4031-4033.
29. Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J, Michiels C. 2000. ERK activation upon hypoxia: Involvement in HIF-1 activation. FEBS Lett 468:53-58.
30. Moses AV, Jarvis MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG, Griffith DJ, Wait CL, Druker BJ, Heinrich MC, Nelson JA, Fruh K. 2002. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 76:8383-8399.
31. Osborne J, Moore PS, Chang Y. 1999. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 60:921-927.
32. Popkov M, Jendreyko N, McGavern DB, Rader C, Barbas CF 3rd. 2005. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res 65:972-981.
33. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. 2005. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352:1317-1323.
34. Stine JT, Wood C, Hill M, Epp A, Raport CJ, Schweickart VI, Endo Y, Sasaki T, Simmons G, Boshoff C, Clapham P, Chang Y, Moore P, Gray PW, Chantry D. 2000. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 95:1151-1157.
35. Sturzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Höschneider PH. 1992. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA 89:7046-7050.
36. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180.
37. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y. 1999. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59:4297-4300.
38. Wang GL, Semenza GL. 1993. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90:4304-4308.
39. Wang L, Wakisaka N, Tomlinson CC, DeWire SM, Krall S, Pagano JS, Damania B. 2004. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 64:2774-2781.
40. West JT, Wood C. 2003. The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene 22:5150-5163.
41. Zacchigna S, Zentilin L, Morini M, Dell'Eva R, Noonan DM, Albini A, Giacca M. 2004. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther 11:73-80.
42. Zhang X, Wang JF, Chandran B, Persaud K, Pytowski B, Fingeroth J, Groopman JE. 2005. Kaposi's sarcoma-associated herpesvirus activation of vascular endothelial growth factor receptor 3 alters endothelial function and enhances infection. J Biol Chem 280:26216-26224.